This benefit was observed even in people without diabetes and was independent of the amount of weight they lost
This may be of benefit for anyone with MCAS, and clinical trials are looking at the effectiveness of different doses.[ref][ref] ( Related article: MCAS) Immune system modulation: The receptor for GLP-1 is found on the cell membrane of macrophages, regulatory T cells, and natural killer T cells
In a Phase 2 obesity trial, participants receiving higher doses achieved up to 24.2% mean weight loss at 48 weeksone of the most impressive results reported for an investigational anti-obesity medication
Metabolic regulatory functions While the vasomodulatory and anti-inflammatory effects of GLP-1RAs target downstream pathological events, their fundamental therapeutic potential may lie in the direct modulation of metabolic dysregulation
Such as Tirzepatide-treated rats developing thyroid C-cell tumors bring up potential human risks inquiries
GLP-1s are a specific type of medication first launched in 2005 for the treatment of type 2 diabetes